Literature DB >> 32413841

L-glutamine ameliorates adipose-hepatic dysmetabolism in OC-treated female rats.

Kehinde Samuel Olaniyi1,2, Lawrence Aderemi Olatunji1.   

Abstract

Adipose dysfunction and inflammation with or without hepatic defects underlie metabolic obesity. Glutamine (GLU) improves glucoregulation and metabolic indices but its effects on adipose function and hepatic lipid deposition in estrogen-progestin oral contraceptive (EPOC) users are unknown. Therefore, we hypothesized that GLUT supplementation would protect against adipose dysfunction and excess hepatic lipid influx and deposition in EPOC-treated animals by suppressing adenosine deaminase/xanthine oxidase (ADA/XO) activity and improving glucose-6-phosphate dehydrogenase (G6PD)-dependent antioxidant defense. Female Wistar rats weighing 150-180 g were allotted into control, GLUT, EPOC and EPOC + GLUT groups (six rats/group). The groups received vehicle (distilled water, p.o.), GLUT (1 g/kg), EPOC containing 1.0 µg ethinylestradiol plus 5.0 µg levonorgestrel and EPOC plus GLUT, respectively, daily for 8 weeks. Results showed that the administration of EPOC caused glucose dysregulation and increased triglyceride-glucose index and visceral adiposity, but the body weight and liver weight were not affected. However, EPOC significantly decreased adipose lipid, G6PD and glutathione and increased glycogen synthesis, ADA, XO, uric acid, lipid peroxidation, lactate production and gamma-glutamyl transferase activity (GGT). On the other hand, EPOC increased hepatic lipid, ADA, XO, uric acid, lipid peroxidation and lactate production and decreased glycogen synthesis, G6PD and glutathione. Nevertheless, supplementation with glutamine attenuated these alterations. Collectively, the present results indicate that EPOC causes metabolically induced obesity which is associated with adipose dysfunction and hepatic metabolic disturbance. The findings also suggest that glutamine confers metabo-protection with corresponding improvement in adipose and hepatic metabolic function by suppression of ADA/XO activity and enhancement of G6PD-dependent antioxidant defense.

Entities:  

Keywords:  adipose function; antioxidant defense; estrogen-progestin; hepatic function; metabolic obesity

Year:  2020        PMID: 32413841     DOI: 10.1530/JOE-19-0582

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

1.  Acetate restores hypothalamic-adipose kisspeptin status in a rat model of PCOS by suppression of NLRP3 immunoreactivity.

Authors:  Kehinde S Olaniyi; Stephanie E Areloegbe; Mosunmola B Oyeleke
Journal:  Endocrine       Date:  2022-09-16       Impact factor: 3.925

2.  Acetate-mediated-obestatin modulation attenuates adipose-hepatic dysmetabolism in high fat diet-induced obese rat model.

Authors:  Kehinde S Olaniyi; Chukwubueze L Atuma; Isaiah W Sabinari; Hadiza Mahmud; Azeezat O Saidi; Adedamola A Fafure; Lawrence A Olatunji
Journal:  Endocrine       Date:  2022-02-28       Impact factor: 3.925

3.  Acetate supplementation restores testicular function by modulating Nrf2/PPAR-γ in high fat diet-induced obesity in Wistar rats.

Authors:  Kehinde S Olaniyi; Christopher O Akintayo; Adesola A Oniyide; Adams O Omoaghe; Mosunmola B Oyeleke; Adedamola A Fafure
Journal:  J Diabetes Metab Disord       Date:  2021-10-21

4.  Acetate rescues defective brain-adipose metabolic network in obese Wistar rats by modulation of peroxisome proliferator-activated receptor-γ.

Authors:  Kehinde Samuel Olaniyi; Morounkeji Nicole Owolabi; Chukwubueze Lucky Atuma; Toluwani Bosede Agunbiade; Bolanle Yemisi Alabi
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

5.  Protective role of melatonin against adipose-hepatic metabolic comorbidities in experimentally induced obese rat model.

Authors:  Mary J Obayemi; Christopher O Akintayo; Adesola A Oniyide; Ayodeji Aturamu; Olabimpe C Badejogbin; Chukwubueze L Atuma; Azeezat O Saidi; Hadiza Mahmud; Kehinde S Olaniyi
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.